Exercise may boost immunotherapy in kidney cancer

NCT ID NCT07680556

Recruiting now Disease control Sponsor: Radboud University Medical Center Source: ClinicalTrials.gov ↗

First seen Jul 02, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This study explores whether adding high-intensity interval training (HIIT) to standard immunotherapy (nivolumab plus ipilimumab) helps patients with advanced kidney cancer. Thirty participants are randomly assigned to either a supervised exercise program or usual care. Researchers will check if the exercise plan is practical and gather early data on immune function, fitness, and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: high-intensity interval training (HIIT)
What this could lead to: If exercise boosts immune response, it could become a low-cost add-on to improve immunotherapy outcomes in kidney cancer.
What could go wrong: This is a small pilot study (30 people) testing feasibility, not effectiveness. Results may not apply to all patients, and exercise may not change cancer outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ONCOLOGY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Motor Activity neoplasm renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ONCOLOGY

Contacts and locations

Locations

Radboudumc
RECRUITING

Nijmegen, Gelderland, Netherlands
Rijnstate
RECRUITING

Arnhem, Gelderland, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.